Caveats regarding the test-negative design to study mpox risk factors and vaccine effectiveness

• by Isaac Núñez

• August 14, 2024

Can LAI-CAB Sustain Long-Term PrEP Use?

A national claims analysis found modest uptake and declining persistence over 2 years despite increasing use of injectable HIV pre-exposure prophylaxis.

• by Andrea Surnit

• July 17, 2026

• 4 min

Weekly HIV Therapy Meets Primary Endpoint

Patients who switched from daily antiretroviral therapy maintained virologic suppression in two phase 3 trials.

• by Kathryn Wighton

• July 23, 2026

• 3 min

Weekly HIV Regimen Meets Phase 3 Goal

The investigational combination pairs islatravir and lenacapavir in a once-weekly single-tablet regimen.

• by Kathryn Wighton

• June 10, 2026

• 2 min